临床研究2024,Vol.32Issue(8) :30-33.DOI:10.12385/j.issn.2096-1278(2024)08-0030-04

孟鲁司特钠片联合阿奇霉素注射液治疗小儿肺炎支原体肺炎的临床疗效

Clinical Efficacy of Montelukast Sodium Tablets Combined with Azithromycin Injection in the Treatment of Mycoplasma Pneumonia in Children

刘素琴
临床研究2024,Vol.32Issue(8) :30-33.DOI:10.12385/j.issn.2096-1278(2024)08-0030-04

孟鲁司特钠片联合阿奇霉素注射液治疗小儿肺炎支原体肺炎的临床疗效

Clinical Efficacy of Montelukast Sodium Tablets Combined with Azithromycin Injection in the Treatment of Mycoplasma Pneumonia in Children

刘素琴1
扫码查看

作者信息

  • 1. 封丘县妇幼保健院 儿科,河南 封丘 453300
  • 折叠

摘要

目的 探究肺炎支原体肺炎患儿接受孟鲁司特钠片与阿奇霉素注射液联合治疗的效果.方法 病例选取时间为 2020 年 6 月至 2023 年 6 月,选择封丘县妇幼保健院在此期间收治的 86 例肺炎支原体患儿作为本次研究对象,以随机数字表法将其分为两组,将 43 例接受单药阿奇霉素注射液治疗的患儿作为对照组,另 43 例接受孟鲁司特钠片联合阿奇霉素注射液治疗的患儿作为实验组,对比两组患儿临床治疗效果、炎性因子[C反应蛋白(CRP)、乳酸脱氢酶(LDH)和铁蛋白(SF)]与影像学检查结果、症状(发热、咳嗽与肺啰音)消失时间与安全性.结果 与对照组相比,实验组患儿治疗有效率较高,症状消失时间缩短,差异有统计学意义(P<0.05).治疗前,两组炎性因子水平差异无统计学意义(P>0.05),治疗后,两组炎性因子水平均降低,且实验组低于对照组,差异有统计学意义(P<0.05).两组患儿不良反应发生率对比差异无统计学意义(P>0.05).影像学检查结果显示,实验组胸腔积液、胸腔增厚、肺不张与肺实变发生率低于对照组,差异有统计学意义(P<0.05).结论 肺炎支原体肺炎患儿接受孟鲁司特钠片联合阿奇霉素注射液治疗后,其治疗效果提升,炎性因子水平降低,症状消失时间缩短,安全可靠,值得临床使用.

Abstract

Objective To explore the effect of Montelukast Sodium Tablets combined with Azithromycin Injection in the treatment of children with Mycoplasma pneumonia.Methods The cases were selected from June 2020 to June 2023,and 86 children with Mycoplasma pneumonia treated in Fengqiu County Maternal and Child Health Hospital during this period were selected as the research subjects.They were divided into two groups by random number table method.43 children who received Azithromycin Injection alone were set as the control group,and another 43 children who received Montelukast Sodium Tablets combined with Azithromycin Injection were set as the experimental group.The clinical treatment effects,inflammatory factors[C-reactive protein(CRP),lactate dehydrogenase(LDH),and serum ferritin(SF)],imaging examination results,symptom(fever,cough,and lung rales)disappearance time,and safety of the two groups were compared.Results Compared with the control group,the treatment effectiveness rate of the experimental group was higher,and the symptom disappearance time was shortened,with statistically significant differences(P<0.05).Before treatment,there was no statistical significance in the comparison of inflammatory factor levels between the two groups(P>0.05).After treatment,the levels of inflammatory factors in both groups decreased,and the experimental group was lower than the control group,with statistically significant differences(P<0.05).There was no statistical significance in the comparison of adverse reaction incidence between the two groups(P>0.05).The imaging examination results showed that the incidence of pleural effusion,pleural thickening,atelectasis,and consolidation in the experimental group was lower than that in the control group,with statistically significant differences(P<0.05).Conclusion After children with Mycoplasma pneumonia receive Montelukast Sodium Tablets combined with Azithromycin Injection,their treatment effect is improved,the level of inflammatory factors is reduced,the symptom disappearance time is shortened,and it is safe and reliable,which is worth using in clinical practice.

关键词

肺炎支原体肺炎/孟鲁司特钠片/阿奇霉素注射液/炎性因子

Key words

mycoplasma pneumonia/montelukast sodium tablets/azithromycin injection/inflammatory factors

引用本文复制引用

出版年

2024
临床研究
西安交通大学

临床研究

影响因子:0.234
ISSN:2096-1278
参考文献量15
段落导航相关论文